Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
V-01 Booster Safety and Immunogenicity After Inactivated Vaccines
NCT05125874Unknown
- Sponsor
- Livzon Pharmaceutical Group Inc.
- Start
- Sep 2021
- Primary completion
- Aug 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Open-label trial of V-01 in coronavirus disease 2019 (COVID-19), sponsored by Livzon Pharmaceutical Group Inc. Primary endpoints: Seroconversion of SARS-CoV-2 neutralizing antibodies at 28 days, Geometric Mean Titer of SARS-CoV-2 neutralizing antibodies at 28 days and 1 more. Status: unknown.
02
Drugs
V-01
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05125874.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05125874.